Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis

References

• Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54:755–71.
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193–200.
   PubMed Web of Science ®Google Scholar
• Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant bacteremia. Diagn Microbiol Infect Dis 2010;67:228–33.
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MVN, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011;204:340–7.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia and treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315–20.
   PubMed Web of Science ®Google Scholar
• Fowler VG, Boucher HW, Corey RG, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65.
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. AHA scientific statement. Circulation 2005;111:e394–434.
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001;345:1318–30.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45:601–8.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, O’Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683–93.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011;52:31–40.
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908–14.
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Noel AR, Tomaselli S, Elliot HC, Bowker KE. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2011;55:867–73.
   PubMed Web of Science ®Google Scholar
• Leonard SN, Vidaillac C, Rybak MJ. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2009;53:2928–33.
   PubMedGoogle Scholar
• Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127–34.
   PubMed Web of Science ®Google Scholar
• Lunde CS, Rexer CH, Hartouni SR, Axt S, Benton BM. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:2198–200.
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 2010;56: 3999–4004.
   Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398–402.
   PubMed Web of Science ®Google Scholar
• Steed ME, Vidaillac C, Rybak MJ. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011;54:955–9.
   Google Scholar
• Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 2019;53:4217–24.
   Google Scholar
• Xiong Q, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011;56:5528–33.
   Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3163–5.
   PubMed Web of Science ®Google Scholar
• Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010;54:5376–8.
   PubMed Web of Science ®Google Scholar
• Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633–8.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. M100–S21. Wayne, PA: CLSI; 2011.
   Google Scholar
• Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:S386–93.
   PubMed Web of Science ®Google Scholar